pediatric oncology
Conditions
Interventions
Group 1: Analysis of liquid biopsy samples from a biobank blood samples of pediatric hematology-oncology patients at initial diagnosis.
Sponsors
Universitätsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin, Klinik für Pädiatrische Onkologie, Hämatologie, Immunologie und Pneumologie
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Pediatric hemato-oncological patients who have been treated and/or are currently being treated at the Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Im Neuenheimer Feld 430, 69120 Heidelberg. Only patients who have provided written consent for the use of residual materials within the framework of the biobank will be included.
Exclusion criteria
Exclusion criteria: Lack of consent or withdrawal of consent to participate in the biobank.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Is a minimally invasive, liquid biopsy–based determination of tumor entity possible at initial diagnosis? | — |
Secondary
| Measure | Time frame |
|---|---|
| Do liquid biopsies allow the identification of genetic alterations as targets for personalized therapies? What prognostic and predictive values can be derived from correlating clinical data (e.g., therapy response, tumor dissemination, outcome, etc.) with the molecular data obtained from the initial liquid biopsy? | — |
Countries
Germany
Contacts
Public ContactFlorian Iser
Universitätsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin, Klinik für Pädiatrische Onkologie, Hämatologie, Immunologie und Pneumologie
Outcome results
None listed